|By PR Newswire||
|April 12, 2014 09:00 AM EDT||
LONDON, April 12, 2014 /PRNewswire/ --
Emerging biological drugs - discover R&D, business analysis, and revenue forecasts
What's the future of biologics, especially new drug classes? Now get the latest technological and commercial analysis. Staying ahead in data and knowledge, you benefit your authority. And you explore trends, developments, results, opportunities, and sales predictions.
So visiongain's new report shows you what's possible for biological drugs - their next phase. There avoid missing out. Instead find progress in that industry and market, discovering expected progress and revenues. See now how you can gain.
New biotechnological medicines will benefit patients and pharmaceutical companies. Read on to explore those therapies, hearing how high revenues can go.
Forecasting and other information showing the most lucrative possibilities for treatments
That study gives you sales forecasts to 2024 at overall world, submarket, product, and national level. See what the future holds, assessing gains for developers and producers.
Many opportunities exist. And besides giving revenue predictions, that new analysis shows recent results, growth rates, and market shares. There you discover 94 tables, 55 charts, and two interviews with authorities in the biopharmaceuticals sector.
And the following sections explain what our new investigation gives you.
Analyses exclusive to that study, showing the most important commercial potentials
In our report you get data found nowhere else. Discover what's really going on. Our forecasting system goes to the core of the biopharmaceutical industry's sales potential like no other work, giving revenue predictions and their meanings.
That analysis benefits your plans, decisions, and influence by interpreting medical needs, R&D, and companies' abilities. You hear what's happening, then, assessing likely gains.
So find in those analyses where potential and money lie, also saving time, worry, and effort.
Prospects for the world market and submarkets - what's possible for pharma biotechnology?
There, in our report, discover overall world sales to 2024 for biologics and new therapies, with discussions.
Also get individual revenue predictions to 2024 for 17 next-generation biologic submarkets at world level:
• Regenerative medicine, with submarket breakdowns for tissue engineering, stem cells, and gene therapies
• Antibodies, including monoclonal antibodies (mAbs), with sub-forecasting for antibody-drug conjugates (ADCs), engineered, and bispecific agents
• Antibody fragments and antibody-like protein (ALP) platforms
• Biosimilars (follow-on protein products).
To see a report overview please email Sara Peerun on [email protected]
And discover other segments' forecasts to 2024:
• Insulins, with submarkets for ultra-long acting, oral, and ultra-rapid-acting insulins
• Growth hormones
• Recombinant coagulation factors
• Other types of next-stage therapeutic proteins.
Next-generation biologics that treat new indications will be launched within 10 years. And you assess outlooks for that expansion in trade, hearing where you could gain.
Our study also explores competition. There you see what's happening for developers, producers, and sellers of new-generation biologics, understanding challenges, trends, and outlooks.
That work also splits its overall world market into leading products, showing where you could profit from new and improved biotech medicines.
Product forecasts for new forms, variations, and uses of biological therapy
How will individual drugs perform to 2024 at world level? Our report predicts revenues of seven top brands:
There you find products and years with highest forecasted sales. And the report predicts those seven therapies will earn combined revenue of more than $10bn in 2024.
You also examine competitors. See what's happening, then, understanding challenges, trends, competition, and opportunities. And here's what that study's author said:
"Next-generation biologics will address shortcomings in current therapies, including inconvenient dosing and concerns over side effects. Developmental trends include sustained release, for less-frequent dosing, and reformulations for oral and topical administration."
That work also gives geographical revenue forecasts.
Healthcare in national markets - what outlooks for business in new biopharma products?
Advances in biotechnology and healthcare expand use of novel biological drugs in developed and developing countries. Also opportunities exist for newer treatments.
And our analyses show you individual revenue forecasts to 2024 for nine national markets:
• United States (US)
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
There you hear about the best sales potentials, appraising national opportunities for next-generation biologicals. See where and how you can profit.
For treating people and saving lives, you explore progress, needs, and possibilities. Find how pharma companies satisfy those demands, also assessing expected financial gains.
And what events influence the biologics industry? What's the outlook for tackling serious diseases? Our work shows you, discussing trends, challenges, and opportunities.
Market forces and issues - what affects biopharma developers, producers, and sellers?
The report explains trends, processes, and events affecting the biopharma industry and market from 2014, including these forces:
• Limitations of existing biologics
• Promise of next-generation biologics, and product launches
• Extension of half-life - pegylation and other technologies
• Demand rising for biological therapies
• Contract manufacturers (CMOs) serving those developmental needs and trends.
To see a report overview please email Sara Peerun on [email protected]
And you explore these influences, among others:
• Disease incidence affecting demand for those more-developed medicines
• Improvements in therapeutic antibodies, including targeted cytotoxic therapies
• R&D pipelines - e.g. for immunotoxins - including agents in clinical development
• Biosimilar insulins likely from 2015 - transformation of that market
• Effects of rising incidence rates in cancer, diabetes, and cardiovascular disorders.
There discover what the future holds. You explore political, economic, social, and technological questions. See too how R&D helps companies benefit patients.
So you explore what progress, trends, and prospects mean. And discover what helps and what hinders players in that healthcare industry, affecting participants' results.
Biological drug technology and applications - companies and 2018 market value
So what happens next? From 2014, novel and biosimilar treatments will benefit patients, doctors, and payers. Those advances will encourage investments, medical progress, and higher revenues from more-advanced biological drugs.
And our study predicts the next-generation biologics market will reach $12.17bn worldwide in 2018, and then multiply in revenues to 2024. See what's possible and what you can gain.
That work also explores activities of these leading companies, among many other firms:
• Eli Lilly
• Novo Nordisk
• Kyowa Hakko Kirin
• Baxter International.
In that market, large pharmaceutical corporations and smaller biopharma specialists can win. See how.
And you find 235 organisations covered. You also get interviews with two companies in the industry, helping you stay ahead. See, then, what the future holds.
Ways Next-Generation Biologics: R&D, Industry and Market 2014-2024 helps
In three main ways our new investigation helps you gain recognition for insight, with data found only there:
• Revenues to 2024 at world level, for 17 submarkets, and 7 products - explore outlooks for production, marketing, and sales
• Forecasts to 2024 for 9 national markets in North America, Europe, and Asia - assess countries for revenues and sales expansions
• Prospects for established competitors, rising companies, and new entrants - investigate portfolios, results, strategies, R&D, and opinions from interviews.
Knowledge there found nowhere else, helping your searches, analyses, and planning
Our new report provides competitive intelligence, showing where progress and money lie.
That work's purpose is to predict sales results with maximum clarity, applicability, and detail. And its research and analyses identify and explain commercial prospects. Now you explore the biological drug industry's future through data exclusive to that study.
So our analysis helps you avoid falling behind in information or missing opportunity. Also it lets you save time and effort. And now your choice could benefit your plans, decisions, and authority - increasing your chances of finding competitive advantages.
Biopharmaceutical knowledge - getting our new report now helps you stay ahead
By trying our new study on emerging biologicals you explore trends, R&D, and sales predictions. There stay ahead - please get that report here now.
To request a report overview please email Sara Peerun at [email protected] or call Tel : +44 (0) 20 7336 6100
Companies Listed in this report:
Adnexus (part of Bristol-Myers Squibb)
Advanced Cell Technology
Agence Nationale de sécurité du Médicament et des produits de santé (ANSM)
Alcon (part of Novartis)
Alfacell (now Tamir Biotechnology)
Applied Genetic Technologies (AGTC)
Biopartners (part of Bioton)
BioVex Group (part of Amgen)
BioWa (part of Kyowa Hakko Kirin)
BrainStorm Cell Therapeutics
Catalent Pharma Solutions
Cellular Dynamics International (CDI)
Centers for Disease Prevention and Control (CDC) [US]
Cephalon (part of Teva)
CEPiA (part of Sanofi)
Children's Hospital of Philadelphia (CHOP)
China Food and Drug Administration (CFDA)
Chugai (part of Roche)
Depuy Mitek (part of J&J)
Dr. Reddy's Laboratories
Duke University Hospital
Elan Pharmaceuticals (now part of Perrigo Company)
EMA's Committee for Medicinal Products for Human Use (CHMP)
Epitomics (part of Abcam)
ESBATech (part of Novartis)
European Medicines Agency (EMA)
Food and Drug Administration (FDA) [US]
Fresenius Biotech (now named Neovii Biotech, part of Neopharm)
Fujifilm Diosynth Biotechnologies
Genentech (part of Roche)
Genzyme (part of Sanofi)
Human Stem Cells Institute (HSCI)
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Germany]
International Diabetes Federation (IDF)
Kyowa Hakko Kirin
LG Life Sciences
MedImmune (part of AstraZeneca)
Merck & Co.
Micromet (part of Amgen)
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
Moorfields Eye Hospital [UK]
National Cancer Institute (NCI) [US]
National Health Service (NHS) [UK]
National Institute for Health and Care Excellence (NICE) [UK]
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [US]
Prolor Biotech (part of OPKO Health)
ratiopharm (part of Teva)
Reliance Life Sciences
Roche Glycart (part of Roche)
Royal Institute of Technology [Sweden]
Russian Ministry of Healthcare (Minzdrav)
Sandoz (part of Novartis)
Scottish Medicines Consortium (SMC)
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech (part of Benda)
Shreya Life Sciences
Spirogen (part of AstraZeneca)
Stelis Biopharmaceuticals (part of Strides Arcolab)
Swedish Orphan Biovitrum (Sobi)
Swiss Federal Institute of Technology
Synthon Biopharmaceuticals (part of Synthon)
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries
Tianjin International Joint Academy of Bio-medicine
University of Toronto
University of California, San Francisco (UCSF)
World Bank Group
World Cancer Research Fund (WCRF)
World Health Organization (WHO)
Wyeth (part of Pfizer)
Yale School of Medicine
To see a report overview please email Sara Peerun on [email protected]
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
Apr. 27, 2017 05:15 AM EDT Reads: 1,344
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in compute, storage and networking technologies, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/...
Apr. 27, 2017 05:00 AM EDT Reads: 2,249
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
Apr. 27, 2017 04:45 AM EDT Reads: 5,402
Judith Hurwitz is president and CEO of Hurwitz & Associates, a Needham, Mass., research and consulting firm focused on emerging technology, including big data, cognitive computing and governance. She is co-author of the book Cognitive Computing and Big Data Analytics, published in 2015. Her Cloud Expo session, "What Is the Business Imperative for Cognitive Computing?" is scheduled for Wednesday, June 8, at 8:40 a.m. In it, she puts cognitive computing into perspective with its value to the busin...
Apr. 27, 2017 03:45 AM EDT Reads: 3,699
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
Apr. 27, 2017 03:45 AM EDT Reads: 1,550
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of Rancher Labs, discussed the technological advances and new business opportunities created by the rapid adoption of containers. With the success of Amazon Web Services (AWS) and various open source technologies used to build private clouds, cloud computing has become an essential component of IT strategy. However, users continue to face challenges in implementing clouds, as older technologies evolve and newer ones like Docker c...
Apr. 27, 2017 03:30 AM EDT Reads: 770
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
Apr. 27, 2017 03:15 AM EDT Reads: 1,165
Everyone wants to use containers, but monitoring containers is hard. New ephemeral architecture introduces new challenges in how monitoring tools need to monitor and visualize containers, so your team can make sense of everything. In his session at @DevOpsSummit, David Gildeh, co-founder and CEO of Outlyer, will go through the challenges and show there is light at the end of the tunnel if you use the right tools and understand what you need to be monitoring to successfully use containers in your...
Apr. 27, 2017 03:15 AM EDT Reads: 2,124
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
Apr. 27, 2017 03:15 AM EDT Reads: 5,963
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
Apr. 27, 2017 02:30 AM EDT Reads: 1,465
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
Apr. 27, 2017 02:15 AM EDT Reads: 834
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists will examine how DevOps helps to meet th...
Apr. 27, 2017 01:15 AM EDT Reads: 1,501
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Apr. 27, 2017 12:45 AM EDT Reads: 619
NHK, Japan Broadcasting, will feature the upcoming @ThingsExpo Silicon Valley in a special 'Internet of Things' and smart technology documentary that will be filmed on the expo floor between November 3 to 5, 2015, in Santa Clara. NHK is the sole public TV network in Japan equivalent to the BBC in the UK and the largest in Asia with many award-winning science and technology programs. Japanese TV is producing a documentary about IoT and Smart technology and will be covering @ThingsExpo Silicon Val...
Apr. 27, 2017 12:00 AM EDT Reads: 9,138
Building a cross-cloud operational model can be a daunting task. Per-cloud silos are not the answer, but neither is a fully generic abstraction plane that strips out capabilities unique to a particular provider. In his session at 20th Cloud Expo, Chris Wolf, VP & Chief Technology Officer, Global Field & Industry at VMware, will discuss how successful organizations approach cloud operations and management, with insights into where operations should be centralized and when it’s best to decentraliz...
Apr. 27, 2017 12:00 AM EDT Reads: 733